Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Health Sciences Trust

JEHSX | Fund

$22.41

$227 M

0.00%

1.05%

Vitals

YTD Return

-3.1%

1 yr return

21.9%

3 Yr Avg Return

4.4%

5 Yr Avg Return

2.1%

Net Assets

$227 M

Holdings in Top 10

40.0%

52 WEEK LOW AND HIGH

$22.8
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.05%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 29.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

$0

IRA

N/A

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Health Sciences Trust

JEHSX | Fund

$22.41

$227 M

0.00%

1.05%

JEHSX - Profile

Distributions

  • YTD Total Return -3.1%
  • 3 Yr Annualized Total Return 4.4%
  • 5 Yr Annualized Total Return 2.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.47%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Health Sciences Trust
  • Fund Family Name
    John Hancock Group of Funds
  • Inception Date
    Apr 30, 2001
  • Shares Outstanding
    N/A
  • Share Class
    Other
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Ziad Bakri

Fund Description

Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies engaged, at the time of investment, in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively, “health sciences”). (The fund will provide written notice to shareholders at least 60 days prior to a change in its 80% investment policy.) While the fund may invest in companies of any size, the majority of its assets are expected to be invested in large- and mid-cap companies. The subadvisor’s portfolio managers divide the health sciences sector into four main areas: pharmaceutical companies, health care services companies, medical products and devices providers, and biotechnology firms. Their allocation among these four areas will vary depending on the relative potential within each area and the outlook for the overall health sciences sector. While most assets will be invested in U.S. common stocks, the fund may purchase other securities, including foreign securities, in keeping with its investment objective. The fund concentrates its investments (invests more than 25% of its total assets) in securities of companies in the health sciences sector, a comparatively narrow segment of the economy, and therefore may experience greater volatility than funds investing in a broader range of industries. In managing the fund, the subadvisor uses a fundamental, bottom-up analysis that seeks to identify high quality companies and the most compelling investment opportunities. In general, the fund will follow a growth investment strategy, seeking companies whose earnings are expected to grow faster than inflation and the economy in general. When stock valuations seem unusually high, however, a “value” approach, which gives preference to seemingly undervalued companies, may also be emphasized. The fund may invest up to 35% of its total assets in foreign securities (including emerging market securities) and may have exposure to foreign currencies through its investment in these securities, its direct holdings of foreign currencies or through its use of foreign currency exchange contracts for the purchase or sale of a fixed quantity of a foreign currency at a future date. In pursuing its investment objective, the fund’s management has the discretion to purchase some securities that do not meet its normal investment criteria, as described above, when it perceives an opportunity for substantial appreciation. These  situations might arise when the fund’s management believes a security could increase in value for a variety of reasons including a change in management, an extraordinary corporate event, or a new product introduction or innovation or a favorable competitive development. The fund may sell securities for a variety of reasons including to realize gains, limit losses or redeploy assets into more promising opportunities. Use of Hedging and Other Strategic Transactions. The fund is authorized to use all of the various investment strategies referred to under “Additional Information About the Funds’ Principal Risks — Hedging, derivatives and other strategic transactions risk” including entering into option transactions.
Read More

JEHSX - Performance

Return Ranking - Trailing

Period JEHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -3.1% -22.9% 20.0% 43.13%
1 Yr 21.9% -20.4% 134.5% 36.88%
3 Yr 4.4%* -6.3% 23.9% 67.50%
5 Yr 2.1%* -15.5% 12.3% 70.32%
10 Yr 8.4%* 3.0% 13.1% 38.58%

* Annualized

Return Ranking - Calendar

Period JEHSX Return Category Return Low Category Return High Rank in Category (%)
2025 3.7% -21.9% 61.0% 85.00%
2024 -4.9% -28.2% 19.2% 70.63%
2023 -1.6% -8.6% 19.0% 75.63%
2022 -23.8% -53.9% 3.2% 91.61%
2021 0.7% -39.6% 24.2% 49.68%

Total Return Ranking - Trailing

Period JEHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -3.1% -22.9% 20.0% 43.13%
1 Yr 21.9% -20.4% 134.5% 36.88%
3 Yr 4.4%* -6.3% 23.9% 67.50%
5 Yr 2.1%* -15.5% 12.3% 70.32%
10 Yr 8.4%* 3.0% 13.1% 38.58%

* Annualized

Total Return Ranking - Calendar

Period JEHSX Return Category Return Low Category Return High Rank in Category (%)
2025 19.5% -0.5% 63.7% 37.50%
2024 1.8% -28.2% 19.2% 61.25%
2023 -1.6% -8.6% 19.0% 91.88%
2022 -13.1% -53.9% 3.7% 73.55%
2021 11.2% -33.9% 26.0% 41.29%

NAV & Total Return History

JEHSX - Holdings

Concentration Analysis

JEHSX Category Low Category High JEHSX % Rank
Net Assets 227 M 6.38 M 37.9 B 66.25%
Number of Holdings 175 24 416 10.00%
Net Assets in Top 10 90.8 M 3.49 M 22.8 B 65.63%
Weighting of Top 10 39.95% 16.2% 79.4% 77.50%

Top 10 Holdings

  1. ELI LILLY and CO COMMON STOCK 10.20%
  2. THERMO FISHER SCIENTIFIC INC COMMON STOCK USD1.0 4.12%
  3. INTUITIVE SURGICAL INC COMMON STOCK USD.001 3.71%
  4. STRYKER CORP COMMON STOCK USD.1 3.52%
  5. MERCK and CO INC COMMON STOCK USD.5 3.48%
  6. ASTRAZENECA PLC COMMON STOCK USD.25 3.22%
  7. UNITEDHEALTH GROUP INC COMMON STOCK USD.01 3.13%
  8. ARGENX SE ADR 2.99%
  9. ABBVIE INC COMMON STOCK USD.01 2.88%
  10. REGENERON PHARMACEUTICALS INC COMMON STOCK USD.001 2.69%

Asset Allocation

Weighting Return Low Return High JEHSX % Rank
Stocks 		99.02% 88.27% 106.13% 38.75%
Cash 		0.74% 0.00% 32.31% 66.88%
Preferred Stocks 		0.14% 0.00% 7.86% 33.13%
Bonds 		0.11% 0.00% 12.39% 10.63%
Other 		0.00% -22.99% 4.13% 83.75%
Convertible Bonds 		0.00% 0.00% 0.37% 87.74%

Stock Sector Breakdown

Weighting Return Low Return High JEHSX % Rank
Healthcare 		98.40% 59.26% 100.00% 85.16%
Basic Materials 		0.91% 0.00% 7.16% 8.39%
Industrials 		0.34% 0.00% 7.02% 3.23%
Financial Services 		0.28% 0.00% 1.60% 10.32%
Technology 		0.07% 0.00% 22.69% 5.16%
Utilities 		0.00% 0.00% 0.00% 85.81%
Real Estate 		0.00% 0.00% 5.89% 87.10%
Energy 		0.00% 0.00% 0.00% 85.81%
Communication Services 		0.00% 0.00% 9.11% 85.81%
Consumer Defense 		0.00% 0.00% 25.73% 87.74%
Consumer Cyclical 		0.00% 0.00% 1.92% 86.45%

Stock Geographic Breakdown

Weighting Return Low Return High JEHSX % Rank
US 		96.85% 60.50% 104.41% 32.50%
Non US 		2.17% 0.00% 36.86% 56.88%

Bond Sector Breakdown

Weighting Return Low Return High JEHSX % Rank
Cash & Equivalents 		0.65% 0.00% 100.00% 55.63%
Derivative 		0.00% -0.01% 0.21% 87.50%
Securitized 		0.00% 0.00% 0.00% 85.61%
Corporate 		0.00% 0.00% 81.57% 88.49%
Municipal 		0.00% 0.00% 0.00% 85.61%
Government 		0.00% 0.00% 29.44% 85.61%

Bond Geographic Breakdown

Weighting Return Low Return High JEHSX % Rank
US 		0.11% 0.00% 11.75% 10.63%
Non US 		0.00% 0.00% 3.33% 86.25%

JEHSX - Expenses

Operational Fees

JEHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.05% 0.08% 4.69% 55.00%
Management Fee 0.86% 0.03% 1.25% 78.13%
12b-1 Fee 0.05% 0.00% 1.00% 16.00%
Administrative Fee 0.25% 0.03% 0.25% 94.44%

Sales Fees

JEHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

JEHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JEHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 29.00% 1.00% 238.00% 21.74%

JEHSX - Distributions

Dividend Yield Analysis

JEHSX Category Low Category High JEHSX % Rank
Dividend Yield 0.00% 0.00% 6.24% 91.25%

Dividend Distribution Analysis

JEHSX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Annual Annual

Net Income Ratio Analysis

JEHSX Category Low Category High JEHSX % Rank
Net Income Ratio -0.47% -2.54% 1.85% 67.97%

Capital Gain Distribution Analysis

JEHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

JEHSX - Fund Manager Analysis

Managers

Ziad Bakri

Start Date

Tenure

Tenure Rank

Apr 01, 2016

6.17

6.2%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 8.08 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.